Are SPACs Good Or Bad For Biopharma?
Special Purpose Acquisition Companies (SPACs) homed in on the biopharma industry in 2020, providing biotech companies with a faster and looser route to the public market. Is there a downside?
You may also be interested in...
The VC market during 2021 was frantic, cash rich and oftentimes appeared to be acting on a “buy now, ask questions later” mentality. With COVID headwinds dwindling, and emerging market uncertainties, what will 2022 bring?
Venture capitalists and industry executives discussed strategies for placing smart bets on emerging gene therapy companies during a recent virtual panel.
For life sciences investors, the past year has been the busiest period in recent memory, say Goodwin partners Sophie McGrath and David Mardle. But what are the industry's drivers and key investor trends in 2021?